Customize your JAMA Network experience by selecting one or more topics from the list below.
D'Amico AV, Schultz D, Loffredo M, et al. Biochemical Outcome Following External Beam Radiation Therapy With or Without Androgen Suppression Therapy for Clinically Localized Prostate Cancer. JAMA. 2000;284(10):1280–1283. doi:10.1001/jama.284.10.1280
Author Affiliations: Joint Center for Radiation Therapy, Brigham and Women's Hospital and Dana Farber Cancer Institute (Drs D'Amico, Dugal, and Hurwitz and Ms Loffredo), Beth Israel Deaconess Medical Center Department of Radiation Oncology (Drs Kaplan and Beard), Department of Pathology, Brigham and Women's Hospital (Dr Renshaw), Department of Medical Oncology, Dana Farber Cancer Institute (Dr Kantoff), Boston, Mass; and Department of Mathematics, Millersville University, Millersville, Pa (Dr Schultz).
Context Combined treatment using radiation therapy (RT) and androgen suppression
therapy (AST) is used to treat men with clinically localized adenocarcinoma
of the prostate, but outcome using this combined therapy compared with RT
alone is not known.
Objective To determine the relative efficacy of RT plus AST vs RT alone among
men with clinically localized prostate cancer.
Design, Setting, and Patients Retrospective cohort study of 1586 men with prostate cancer who were
treated between January 1989 and August 1999 using 3-dimensional conformal
RT with (n = 276) or without (n = 1310) 6 months of AST.
Main Outcome Measure Relative risk (RR) of prostate-specific antigen (PSA) failure (defined
according to the American Society for Therapeutic Radiology and Oncology consensus
statement), by treatment and high-, intermediate-, or low-risk group based
on serum PSA level, biopsy Gleason score, and 1992 American Joint Commission
on Cancer clinical tumor category.
Results Estimates of 5-year PSA outcome after RT with or without AST were not
statistically different among low-risk patients (P
= .09), whereas intermediate- and high-risk patients treated with RT plus
AST had significantly better outcomes than those treated with RT alone (P<.001 and = .009, respectively). The RR of PSA failure
in low-risk patients treated with RT plus AST was 0.5 (95% confidence interval
[CI], 0.3-1.1) compared with patients treated with RT alone. The RRs of PSA
failure in intermediate-risk and high-risk patients treated with RT plus AST
compared with RT alone were 0.2 (95% CI, 0.1-0.3) and 0.4 (95% CI, 0.2-0.8),
Conclusions Our data suggest a significant benefit in 5-year PSA outcomes for men
with clinically localized prostate cancer in intermediate- and high-risk groups
treated with RT plus AST vs those treated with RT alone. Results from prospective
randomized trials currently under way are needed to validate these findings.
Create a personal account or sign in to: